Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status:
Completed
Trial end date:
2018-03-09
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of
ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with
acne vulgaris.